PMID- 14742187
OWN - NLM
STAT- MEDLINE
DCOM- 20040311
LR  - 20210526
IS  - 0066-4804 (Print)
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 48
IP  - 2
DP  - 2004 Feb
TI  - Antibody array-generated profiles of cytokine release from THP-1 leukemic 
      monocytes exposed to different amphotericin B formulations.
PG  - 396-403
AB  - Cytokine antibody arrays were used to establish the profiles of cytokine release 
      from THP-1 monocytes exposed to different amphotericin B (AMB) drug delivery 
      systems. Fungizone (FZ) and Amphotec (ABCD) caused the release of significantly 
      more inflammatory molecules and the release of inflammatory molecules at higher 
      levels than either AmBisome (L-AMB) or Abelcet (ABLC) after 6 h of treatment. 
      Specifically, tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), 
      GRO-(alphabetagamma), monocyte chemoattractant protein-1 (MCP-1), RANTES, IL-10, 
      and IL-6 were detected and semiquantified with a chemiluminscence imaging system. 
      TNF-alpha, IL-8, and MCP-1 were the most predominant; however, little if any 
      TNF-alpha was present in ABLC- or L-AMB-treated cultures. The TNF- alpha and IL-8 
      levels determined by quantitative enzyme-linked immunosorbent assay correlated 
      with the relative cytokine levels measured by using the antibody arrays. Although 
      the viabilities of THP-l monocytes in all AMB-treated cultures were similar by 
      trypan blue exclusion, the amount of lactic dehydrogenase released was 
      significantly larger in FZ- and ABCD-treated cultures than in L-AMB- and 
      ABLC-treated cultures, indicating more membrane perturbations with those 
      formulations. Membrane cation channel formation was also measured in model 
      cholesterol-containing large unilamellar vesicles to directly assess the ion 
      channel formation ability of the system. Only FZ and ABCD induced significant ion 
      currents at concentrations less than 1.5 x 10(-5) M. These results may help 
      provide rationales for the immediate cytokine-mediated side effects observed with 
      FZ and ABCD and the reduced side effects observed with L-AMB and ABLC.
FAU - Turtinen, Lloyd W
AU  - Turtinen LW
AD  - Department of Biology, University of Wisconsin-Eau Claire, Eau Claire, Wisconsin 
      54702, USA. Turtinen@uwec.edu
FAU - Prall, David N
AU  - Prall DN
FAU - Bremer, Lindsay A
AU  - Bremer LA
FAU - Nauss, Rachel E
AU  - Nauss RE
FAU - Hartsel, Scott C
AU  - Hartsel SC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Antibodies)
RN  - 0 (Antifungal Agents)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Ion Channels)
RN  - 0 (Proteome)
RN  - 7XU7A7DROE (Amphotericin B)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Amphotericin B/*pharmacology
MH  - *Antibodies
MH  - Antifungal Agents/*pharmacology
MH  - Cell Division/drug effects
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Chemistry, Pharmaceutical
MH  - Chemokines/metabolism
MH  - Cytokines/immunology/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Ion Channels/drug effects/metabolism
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Microscopy, Fluorescence
MH  - Monocytes/drug effects/*metabolism
MH  - Proteome
PMC - PMC321531
EDAT- 2004/01/27 05:00
MHDA- 2004/03/12 05:00
PMCR- 2004/02/01
CRDT- 2004/01/27 05:00
PHST- 2004/01/27 05:00 [pubmed]
PHST- 2004/03/12 05:00 [medline]
PHST- 2004/01/27 05:00 [entrez]
PHST- 2004/02/01 00:00 [pmc-release]
AID - 0611 [pii]
AID - 10.1128/AAC.48.2.396-403.2004 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2004 Feb;48(2):396-403. doi: 
      10.1128/AAC.48.2.396-403.2004.